Skip to main content
Premium Trial:

Request an Annual Quote

CuraGen s Revenues Fall, Losses Narrow in Q4

NEW YORK, Feb. 5 (GenomeWeb News) - CuraGen reported falling revenues and smaller losses for the fourth quarter of 2003 today.


Revenues for the quarter decreased to $2.5 million from $3.8 million a year ago.


CuraGen's R&D expenses decreased to $16.6 million, from $18 million during the same period last year.


The company's net loss for the quarter narrowed to $17.5 million, or $.35 per share, from $28.9 million, or $.59 per share, for the year-ago period.


As of Dec. 31, CuraGen had cash and investments of $343.6 million.


CuraGen said it will continue to focus on clinical studies of its protein, antibody, and small molecule therapeutics this year. Its whole genome sequencing subsidiary, 454 Life Sciences, is planning to bring its first product to market this year.


The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more